

## AMENDMENTS

### In the Claims:

Please cancel claims 1-28.

Please add the following new claims:

29. A method for inhibiting HIV infection of a cell comprising the step of contacting said cell with a composition comprising a peptide of 8 to 24 residues comprising the sequence RAFVTIGK.

30. The method of claim 29, wherein said peptide is 8 residues in length.

31. The method of claim 29, wherein said peptide is 15 residues in length.

32. The method of claim 31, wherein said peptide comprises the sequence RIQRGPGRAFVTIGK.

33. The method of claim 29, wherein said peptide is 24 amino acids in length.

34. The method of claim 33, wherein said peptide comprises the sequence NNTRKSIRIQRGPGRAFVTIGKIG.

35. The method of claim 29, wherein said peptide is in the form of a multimer.

36. The method of claim 35, wherein said multimer comprises a single chain comprising repeating units of said peptide.

37. The method of claim 36, wherein said repeating units are bonded through one or two cysteine residues.

38. The method of claim 35, wherein said multimer comprises a spacer peptide to which multiple copies of said peptide are bonded.

39. The method of claim 38, wherein said spacer peptide comprises glycyl residues to which each of said multiple copies of said peptide are bonded.

40. The method of claim 38, wherein said spacer peptide forms a surfactant-like micelle.

41. The method of claim 29, wherein said composition is dispersed in a pharmaceutically acceptable aqueous medium.

42. The method of claim 29, wherein said composition is administered at a dosage range of between about 10 micrograms to about 500 milligrams.

43. The method of claim 40, wherein dosage range is about 50 micrograms to about 1 milligram.

44. The method of claim 41, wherein said dosage range is about 100 micrograms.

45. The method of claim 29, further comprising contacting said cell with said composition a second time.

46. The method of claim 29, wherein said cell is in a human subject.

47. The method of claim 46, wherein said contacting comprises injection of said composition.

48. A method for inhibiting entry of HIV into a cell comprising the step of contacting said cell with a peptide of 8 to 24 residues comprising the sequence RAFVTIGK. --

No fees are believed to be due in connection with the filing of this Preliminary Amendment; however, should any fees under 37 C.F.R §§ 1.16 to 1.21 be deemed necessary for any reason relating to the enclosed materials, the Commissioner is hereby authorized to deduct said fees from Arnold, White & Durkee Deposit Account No. 01-2508/UTXC:538/HYL.

Respectfully submitted,

Steven L. Highlander  
Reg. No. 37,642

ARNOLD, WHITE & DURKEE  
P. O. Box 4433  
Houston, Texas 77210  
(512) 320-7200

bcc: BethLynn Maxwell, Ph.D.  
Mr. William J. Doty  
Dr. Ralph B. Arlinghaus, Ph.D.  
Dr. Jagannadha K. Sastry  
Louis T. Pirkey, Esq.  
David L. Parker, Esq.

2025-03-26 14:00:00